278 related articles for article (PubMed ID: 24828076)
21. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
22. The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
Spurgeon SE; Coffey G; Fletcher LB; Burke R; Tyner JW; Druker BJ; Betz A; DeGuzman F; Pak Y; Baker D; Pandey A; Hollenbach SJ; Sinha U; Loriaux MM
J Pharmacol Exp Ther; 2013 Feb; 344(2):378-87. PubMed ID: 23220742
[TBL] [Abstract][Full Text] [Related]
23. Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.
Carsetti L; Laurenti L; Gobessi S; Longo PG; Leone G; Efremov DG
Cell Signal; 2009 Jul; 21(7):1187-94. PubMed ID: 19296913
[TBL] [Abstract][Full Text] [Related]
24. Can treating the SYK cell cure leukemia?
Downing JR
Cancer Cell; 2009 Oct; 16(4):270-1. PubMed ID: 19800569
[TBL] [Abstract][Full Text] [Related]
25. Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Feng G; Wang X
Leuk Lymphoma; 2014 Dec; 55(12):2699-705. PubMed ID: 24547708
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma.
Bernard S; Danglade D; Gardano L; Laguillier C; Lazarian G; Roger C; Thieblemont C; Marzec J; Gribben J; Cymbalista F; Varin-Blank N; Ledoux D; Baran-Marszak F
Int J Cancer; 2015 Jun; 136(12):2761-74. PubMed ID: 25388373
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³⁴⁸) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Bourgne C; Janel A; Berger J; Rapatel C; Tournilhac O; Hermet E; Guerci A; Lioret F; Briançon A; Bamdad M; Boiret-Dupré N; Berger MG
Leuk Res; 2015 Mar; 39(3):329-34. PubMed ID: 25612940
[TBL] [Abstract][Full Text] [Related]
28. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
29. The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Hilgendorf I; Eisele S; Remer I; Schmitz J; Zeschky K; Colberg C; Stachon P; Wolf D; Willecke F; Buchner M; Zirlik K; Ortiz-Rodriguez A; Lozhkin A; Hoppe N; von zur Muhlen C; zur Hausen A; Bode C; Zirlik A
Arterioscler Thromb Vasc Biol; 2011 Sep; 31(9):1991-9. PubMed ID: 21700926
[TBL] [Abstract][Full Text] [Related]
30. SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric
Serafin V; Porcù E; Cortese G; Mariotto E; Veltri G; Bresolin S; Basso G; Accordi B
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817853
[TBL] [Abstract][Full Text] [Related]
31. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
Burke RT; Meadows S; Loriaux MM; Currie KS; Mitchell SA; Maciejewski P; Clarke AS; Dipaolo JA; Druker BJ; Lannutti BJ; Spurgeon SE
Oncotarget; 2014 Feb; 5(4):908-15. PubMed ID: 24659719
[TBL] [Abstract][Full Text] [Related]
32. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia.
Boros K; Puissant A; Back M; Alexe G; Bassil CF; Sinha P; Tholouli E; Stegmaier K; Byers RJ; Rodig SJ
Oncotarget; 2015 Sep; 6(28):25575-87. PubMed ID: 26315286
[TBL] [Abstract][Full Text] [Related]
33. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Riccaboni M; Bianchi I; Petrillo P
Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
[TBL] [Abstract][Full Text] [Related]
34. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Uckun FM; Qazi S
Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Flinn IW; Bartlett NL; Blum KA; Ardeshna KM; LaCasce AS; Flowers CR; Shustov AR; Thress KS; Mitchell P; Zheng F; Skolnik JM; Friedberg JW
Eur J Cancer; 2016 Feb; 54():11-17. PubMed ID: 26707592
[TBL] [Abstract][Full Text] [Related]
36. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
Kapoor S
J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
[No Abstract] [Full Text] [Related]
37. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.
Braselmann S; Taylor V; Zhao H; Wang S; Sylvain C; Baluom M; Qu K; Herlaar E; Lau A; Young C; Wong BR; Lovell S; Sun T; Park G; Argade A; Jurcevic S; Pine P; Singh R; Grossbard EB; Payan DG; Masuda ES
J Pharmacol Exp Ther; 2006 Dec; 319(3):998-1008. PubMed ID: 16946104
[TBL] [Abstract][Full Text] [Related]
38. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
39. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
40. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
Norman P
Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
